"Your Guide To Emerging Cancer Therapeutics"

Anna Johansson Anna.Johansson at bioseeker.com
Mon Apr 29 11:42:06 EST 2002


Several emerging cancer therapeutics are in line for commercialization. The most 
prominent groups are angiogenesis inhibitors, apoptosis inducers, telomerase modifiers, immunotherapy and gene therapy. Promising new
therapies trigger the immune system to enhance tumor cell destruction. BioSeeker Group has identified over one hundred companies that are competing in the fields of cancer immunotherapy and cancer gene therapy and has compiled their status into a number of developmental reports.
BioSeeker Group can now bring you up to date with immunotherapy and gene
therapy for cancer in our new Business Reports:

"Commercializing On Tumor Antigens: Analytical Perspectives"
www.commercializing-tumor-antigens.info  

"The Competitive Landscape of Gene Therapy"
www.competitive-landscape-gene-therapy.info  

"Emerging Cancer Therapeutics"
www.emerging-cancer-therapeutics.info  

"Cancer Immunotherapy Beyond Monoclonals"
www.cancer-immunotherapy-beyond-monoclonals.info  

"Year 2001 Achievements in Cancer Vaccine R&D"
www.year2001-achievements-cancer-vaccine.info  

Order fax: +46-8-56849191
Order phone: +46-8-56849192

Coming Report
"Ion Channel Assays in the Drug Discovery Process" (May, 2002)
For more information please contact us at BioInfo at BioSeeker.com  

Other Reports
"Anti-fungal R&D"
 www.anti-fungal.info  


"Pan European Investors in Biotechnology"
www.pan-european-investors-biotechnology.info  


"Swedish Biotech Industry"
www.swedishbiotech.info   

Order fax: +46-8-56849191
Order phone: +46-8-56849192 

************************
BioSeeker Group AB
Björnnäsvägen 21
SE-113 47 STOCKHOLM
SWEDEN
BioInfo at BioSeeker.com
www.BioSeeker.com

This electronic letter has been sent to you personally in the belief that it would be of interest to you and is not part of a mailing list.
If you feel this message has been sent to you in error please reply with remove to unsubscribe at bioseeker.com

---




More information about the Dros mailing list